Aerosolized antibiotics in cystic fibrosis: current and future trends

References

• Cystic Fibrosis Foundation. Patient Registry: Annual Data Report, 2005. Cystic Fibrosis Foundation, Bethesda, MD, USA (2006).
   Google Scholar
• Valerius NH, Koch C, Hoiby N. Prevention of chronic Pseudomonas aeruginosa colonisation in cystic fibrosis by early treatment. Lancet338(8769), 725–726 (1991).
   PubMed Web of Science ®Google Scholar
• Frederiksen B, Koch C, Hoiby N. Antibiotic treatment of initial colonization with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration of pulmonary function in cystic fibrosis. Pediatr. Pulmonol.23(5), 330–335 (1997).
   PubMed Web of Science ®Google Scholar
• Ramsey BW, Pepe MS, Quan JM et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. N. Engl. J. Med.340(1), 23–30 (1999).
   PubMed Web of Science ®Google Scholar
• Prober CG, Walson PD, Jones J. Technical report: precautions regarding the use of aerosolized antibiotics. Committee on Infectious Diseases and Committee on Drugs. Pediatrics106(6), E89 (2000).
   PubMed Web of Science ®Google Scholar
• di Sant’Agnese PEA, Andersen D. Celiac Syndrome. IV. Chemotherapy in infections of the respiratory tract associated with cystic fibrosis of the pancreas; observations with penicillin and drugs of the sulfonamide group, with special reference to penicillin aerosol. Am. J. Dis. Child.72, 17–61 (1946).
   Google Scholar
• Touw DJ, Brimicombe RW, Hodson ME, Heijerman HG, Bakker W. Inhalation of antibiotics in cystic fibrosis. Eur. Respir. J.8(9), 1594–1604 (1995).
   PubMed Web of Science ®Google Scholar
• Sexauer WP, Fiel SB. Aerosolized antibiotics in cystic fibrosis. Semin. Respir. Crit. Care Med.24(6), 717–726 (2003).
   PubMed Web of Science ®Google Scholar
• Flume P, Klepser ME. The rationale for aerosolized antibiotics. Pharmacotherapy22(3 Pt 2), S71–S79 (2002).
   PubMed Web of Science ®Google Scholar
• Hodson ME, Gallagher CG, Govan JR. A randomised clinical trial of nebulised tobramycin or colistin in cystic fibrosis. Eur. Respir. J.20(3), 658–664 (2002).
   PubMed Web of Science ®Google Scholar
• Murphy TD, Anbar RD, Lester LA et al. Treatment with tobramycin solution for inhalation reduces hospitalizations in young CF subjects with mild lung disease. Pediatr. Pulmonol.38(4), 314–320 (2004).
   PubMed Web of Science ®Google Scholar
• Gibson RL, Burns JL, Ramsey BW. Pathophysiology and management of pulmonary infections in cystic fibrosis. Am. J. Respir. Crit. Care Med.168(8), 918–951 (2003).
   PubMed Web of Science ®Google Scholar
• Ratjen F. Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis. Curr. Opin. Pulm. Med.12(6), 428–432 (2006).
   PubMed Web of Science ®Google Scholar
• Taccetti G, Campana S, Festini F, Mascherini M, Doring G. Early eradication therapy against Pseudomonas aeruginosa in cystic fibrosis patients. Eur. Respir. J.26(3), 458–461 (2005).
   PubMed Web of Science ®Google Scholar
• Baumann U, Mansouri E, von Specht BU. Recombinant OprF–OprI as a vaccine against Pseudomonas aeruginosa infections. Vaccine22(7), 840–847 (2004).
   PubMed Web of Science ®Google Scholar
• Burns JL, Van Dalfsen JM, Shawar RM et al. Effect of chronic intermittent administration of inhaled tobramycin on respiratory microbial flora in patients with cystic fibrosis. J. Infect. Dis.179(5), 1190–1196 (1999).
   PubMed Web of Science ®Google Scholar
• Worlitzsch D, Tarran R, Ulrich M et al. Effects of reduced mucus oxygen concentration in airway Pseudomonas infections of cystic fibrosis patients. J. Clin. Invest.109(3), 317–325 (2002).
   PubMed Web of Science ®Google Scholar
• Boucher RC. New concepts of the pathogenesis of cystic fibrosis lung disease. Eur. Respir. J.23(1), 146–158 (2004).
   PubMed Web of Science ®Google Scholar
• Kuhn RJ. Formulation of aerosolized therapeutics. Chest120(3 Suppl.), S94–S98 (2001).
   PubMed Web of Science ®Google Scholar
• Kuhn RJ. Pharmaceutical considerations in aerosol drug delivery. Pharmacotherapy22(3 Pt 2), S80–S85 (2002).
   PubMed Web of Science ®Google Scholar
• Littlewood JM, Miller MG, Ghoneim AT, Ramsden CH. Nebulised colomycin for early Pseudomonas colonisation in cystic fibrosis. Lancet1(8433), 865 (1985).
   PubMed Web of Science ®Google Scholar
• Crowther Labiris NR, Holbrook AM, Chrystyn H, Macleod SM, Newhouse MT. Dry powder versus intravenous and nebulized gentamicin in cystic fibrosis and bronchiectasis. A pilot study. Am. J. Respir. Crit. Care Med.160(5 Pt 1), 1711–1716 (1999).
   PubMed Web of Science ®Google Scholar
• Schaad UB, Wedgwood-Krucko J, Suter S, Kraemer R. Efficacy of inhaled amikacin as adjunct to intravenous combination therapy (ceftazidime and amikacin) in cystic fibrosis. J. Pediatr.111(4), 599–605 (1987).
   PubMed Web of Science ®Google Scholar
• Gibson RL, Retsch-Bogart GZ, Oermann C et al. Microbiology, safety, and pharmacokinetics of aztreonam lysinate for inhalation in patients with cystic fibrosis. Pediatr. Pulmonol.41(7), 656–665 (2006).
   PubMed Web of Science ®Google Scholar
• Ledson MJ, Gallagher MJ, Robinson M et al. A randomized double-blinded placebo-controlled crossover trial of nebulized taurolidine in adult cystic fibrosis patients infected with Burkholderia cepacia. J. Aerosol. Med.15(1), 51–57 (2002).
   PubMedGoogle Scholar
• Estes L. Review of pharmacokinetics and pharmacodynamics of antimicrobial agents. Mayo Clin. Proc.73(11), 1114–1122 (1998).
   PubMedGoogle Scholar
• Touw DJ, Jacobs FA, Brimicombe RW et al. Pharmacokinetics of aerosolized tobramycin in adult patients with cystic fibrosis. Antimicrob. Agents Chemother.41(1), 184–187 (1997).
   PubMed Web of Science ®Google Scholar
• Alothman GA, Alsaadi MM, Ho BL et al. Evaluation of bronchial constriction in children with cystic fibrosis after inhaling two different preparations of tobramycin. Chest122(3), 930–934 (2002).
   PubMed Web of Science ®Google Scholar
• Mouton JW, Dudley MN, Cars O, Derendorf H, Drusano GL. Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: an update. J. Antimicrob. Chemother.55(5), 601–607 (2005).
   PubMed Web of Science ®Google Scholar
• LiPuma JJ. Microbiological and immunologic considerations with aerosolized drug delivery. Chest120(3 Suppl.), S118–S123 (2001).
   Web of Science ®Google Scholar
• Westerman EM, Heijerman HG, Frijlink HW. Dry powder inhalation versus wet nebulisation delivery of antibiotics in cystic fibrosis patients. Expert Opin. Drug Deliv.4(2), 91–94 (2007).
   PubMed Web of Science ®Google Scholar
• Eisenberg J, Pepe M, Williams-Warren J et al. A comparison of peak sputum tobramycin concentration in patients with cystic fibrosis using jet and ultrasonic nebulizer systems. Aerosolized Tobramycin Study Group. Chest111(4), 955–962 (1997).
   PubMed Web of Science ®Google Scholar
• Mendelman PM, Smith AL, Levy J et al. Aminoglycoside penetration, inactivation, and efficacy in cystic fibrosis sputum. Am. Rev. Respir. Dis.132(4), 761–765 (1985).
   PubMed Web of Science ®Google Scholar
• Cooney GF, Lum BL, Tomaselli M, Fiel SB. Absolute bioavailability and absorption characteristics of aerosolized tobramycin in adults with cystic fibrosis. J. Clin. Pharmacol.34(3), 255–259 (1994).
   PubMed Web of Science ®Google Scholar
• Dopfer R, Brand P, Mullinger B et al. Inhalation of tobramycin in patients with cystic fibrosis: comparison of two methods. J. Physiol. Pharmacol.58(Suppl. 5 Pt 1), 141–154 (2007).
   PubMedGoogle Scholar
• Geller DE, Konstan MW, Smith J, Noonberg SB, Conrad C. Novel tobramycin inhalation powder in cystic fibrosis subjects: pharmacokinetics and safety. Pediatr. Pulmonol.42(4), 307–313 (2007).
   PubMed Web of Science ®Google Scholar
• Fok TF, Monkman S, Dolovich M et al. Efficiency of aerosol medication delivery from a metered dose inhaler versus jet nebulizer in infants with bronchopulmonary dysplasia. Pediatr. Pulmonol.21(5), 301–309 (1996).
   PubMed Web of Science ®Google Scholar
• Hagerman JK, Hancock KE, Klepser ME. Aerosolised antibiotics: a critical appraisal of their use. Expert Opin. Drug Deliv.3(1), 71–86 (2006).
   PubMedGoogle Scholar
• Retsch-Bogart GZ, Burns JL, Otto KL et al. A Phase 2 study of aztreonam lysine for inhalation to treat patients with cystic fibrosis and Pseudomonas aeruginosa infection. Pediatr. Pulmonol.43(1), 47–58 (2008).
   PubMed Web of Science ®Google Scholar
• Le Brun PP, de Boer AH, Mannes GP et al. Dry powder inhalation of antibiotics in cystic fibrosis therapy: part 2. Inhalation of a novel colistin dry powder formulation: a feasibility study in healthy volunteers and patients. Eur. J. Pharm. Biopharm.54(1), 25–32 (2002).
   PubMed Web of Science ®Google Scholar
• Meers P, Neville M, Malinin V et al. Biofilm penetration, triggered release and in vivo activity of inhaled liposomal amikacin in chronic Pseudomonas aeruginosa lung infections. J. Antimicrob. Chemother.61(4), 859–868 (2008).
   PubMed Web of Science ®Google Scholar
• Halwani M, Mugabe C, Azghani AO et al. Bactericidal efficacy of liposomal aminoglycosides against Burkholderia cenocepacia.J. Antimicrob. Chemother.60(4), 760–769 (2007).
   PubMed Web of Science ®Google Scholar
• Shah SP, Misra A. Liposomal amikacin dry powder inhaler: effect of fines on in vitro performance. AAPS PharmSciTech.5(4), e65 (2004).
   PubMed Web of Science ®Google Scholar
• Mugabe C, Azghani AO, Omri A. Preparation and characterization of dehydration–rehydration vesicles loaded with aminoglycoside and macrolide antibiotics. Int. J. Pharm.307(2), 244–250 (2006).
   PubMed Web of Science ®Google Scholar
• Fuchs HJ, Borowitz DS, Christiansen DH et al. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group. N. Engl. J. Med.331(10), 637–642 (1994).
   PubMed Web of Science ®Google Scholar
• Munck A, Bonacorsi S, Mariani-Kurkdjian P et al. Genotypic characterization of Pseudomonas aeruginosa strains recovered from patients with cystic fibrosis after initial and subsequent colonization. Pediatr. Pulmonol.32(4), 288–292 (2001).
   PubMedGoogle Scholar
• Foweraker JE, Laughton CR, Brown DF, Bilton D. Phenotypic variability of Pseudomonas aeruginosa in sputa from patients with acute infective exacerbation of cystic fibrosis and its impact on the validity of antimicrobial susceptibility testing. J. Antimicrob. Chemother.55(6), 921–927 (2005).
   PubMed Web of Science ®Google Scholar
• Smith AL, Fiel SB, Mayer-Hamblett N, Ramsey B, Burns JL. Susceptibility testing of Pseudomonas aeruginosa isolates and clinical response to parenteral antibiotic administration: lack of association in cystic fibrosis. Chest123(5), 1495–1502 (2003).
   PubMed Web of Science ®Google Scholar
• Aaron SD, Vandemheen KL, Ferris W et al. Combination antibiotic susceptibility testing to treat exacerbations of cystic fibrosis associated with multiresistant bacteria: a randomised, double-blind, controlled clinical trial. Lancet366(9484), 463–471 (2005).
   PubMed Web of Science ®Google Scholar
• Moss RB. Administration of aerosolized antibiotics in cystic fibrosis patients. Chest120(3 Suppl.), S107–S113 (2001).
   PubMed Web of Science ®Google Scholar
• Govan JR. Insights into cystic fibrosis microbiology from the European tobramycin trial in cystic fibrosis. J. Cyst. Fibros.1(Suppl. 2), 203–208 (2002).
   PubMedGoogle Scholar